Wednesday, June 11, 2014

Seeking Alpha: Neurocrine In "Hurry Up And Wait" Mode

"Long moments of boredom punctuated by moments of sheer terror" is a relatively common expression used in reference to war, but it can also apply to biotech investing, to a limited extent. Stocks like Neurocrine Biosciences (NBIX) are inarguably driven in large part by relatively infrequent news on clinical trial outcomes and partnering arrangements, with the shares left to drift on speculation and overall biotech sentiment in the long spaces between.

Neurocrine management is certainly not just sitting on its hands as they work to put '854 into Phase III development for tardive dyskinesia and Phase II development for Tourette's, and as partner AbbVie (ABBV) moves Elagolix through clinical trials in endometriosis and uterine fibroids. Between final agreement on a Phase III '854 protocol and top line data from one Phase III endometriosis study, investors still have important data to look forward to this year, but there will be some long waits in between.

Continue reading here:
Neurocrine In "Hurry Up And Wait" Mode

No comments: